PT2371856T - Modificação de fviii direcionada a sítio - Google Patents

Modificação de fviii direcionada a sítio

Info

Publication number
PT2371856T
PT2371856T PT111532974T PT11153297T PT2371856T PT 2371856 T PT2371856 T PT 2371856T PT 111532974 T PT111532974 T PT 111532974T PT 11153297 T PT11153297 T PT 11153297T PT 2371856 T PT2371856 T PT 2371856T
Authority
PT
Portugal
Prior art keywords
fviii
site
directed modification
modification
directed
Prior art date
Application number
PT111532974T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2371856(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PT2371856T publication Critical patent/PT2371856T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
PT111532974T 2004-11-12 2005-11-14 Modificação de fviii direcionada a sítio PT2371856T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12

Publications (1)

Publication Number Publication Date
PT2371856T true PT2371856T (pt) 2022-08-12

Family

ID=36337298

Family Applications (4)

Application Number Title Priority Date Filing Date
PT111532974T PT2371856T (pt) 2004-11-12 2005-11-14 Modificação de fviii direcionada a sítio
PT58493925T PT1824988T (pt) 2004-11-12 2005-11-14 Mutagénese de fviii dirigida ao local
PT161869011T PT3130601T (pt) 2004-11-12 2005-11-14 Modificação de fviii dirigida ao local
PT111533006T PT2363414T (pt) 2004-11-12 2005-11-14 Modificação de fviii direcionada a sítio

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT58493925T PT1824988T (pt) 2004-11-12 2005-11-14 Mutagénese de fviii dirigida ao local
PT161869011T PT3130601T (pt) 2004-11-12 2005-11-14 Modificação de fviii dirigida ao local
PT111533006T PT2363414T (pt) 2004-11-12 2005-11-14 Modificação de fviii direcionada a sítio

Country Status (32)

Country Link
US (4) US7632921B2 (instruction)
EP (9) EP3243833B1 (instruction)
JP (5) JP2008524117A (instruction)
KR (7) KR20120136413A (instruction)
CN (6) CN105753968A (instruction)
AU (1) AU2005304622B2 (instruction)
BE (1) BE2019C523I2 (instruction)
BR (2) BRPI0517795B8 (instruction)
CA (1) CA2586379C (instruction)
CY (3) CY1119292T1 (instruction)
DK (3) DK1824988T3 (instruction)
ES (4) ES2633916T3 (instruction)
FR (1) FR19C1031I2 (instruction)
HN (1) HN2007015683A (instruction)
HR (2) HRP20070268B1 (instruction)
HU (5) HUE033776T2 (instruction)
IL (3) IL182903A (instruction)
LT (5) LT1824988T (instruction)
LU (1) LUC00118I2 (instruction)
MA (1) MA29663B1 (instruction)
MX (3) MX2007005466A (instruction)
NL (1) NL300989I2 (instruction)
NO (3) NO20210454A1 (instruction)
NZ (1) NZ555032A (instruction)
PH (2) PH12014500352B1 (instruction)
PL (3) PL2371856T3 (instruction)
PT (4) PT2371856T (instruction)
RU (1) RU2423380C2 (instruction)
SI (4) SI2363414T1 (instruction)
UA (1) UA95225C2 (instruction)
WO (1) WO2006053299A2 (instruction)
ZA (1) ZA200703696B (instruction)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
SI2363414T1 (sl) 2004-11-12 2022-09-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
MX2007008229A (es) 2005-01-10 2007-09-11 Neose Technologies Inc Factor estimulador de colonias de granulocitos glicopegilado.
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
MX2008014685A (es) * 2006-05-24 2008-11-27 Novo Nordisk Healthcare Ag Analogos de factor ix con semivida prolongada in vivo.
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
WO2008074032A1 (en) 2006-12-15 2008-06-19 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
GB2467700A (en) 2007-11-09 2010-08-11 Baxter Int Modified recombinant Factor VIII and von Willebrand Factor and methods of use
CA2715465C (en) 2008-02-27 2017-03-21 Novo Nordisk A/S Conjugated factor viii molecules
CN104045716A (zh) 2008-05-16 2014-09-17 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
US20110286988A1 (en) * 2008-06-04 2011-11-24 Bayer Healthcare Llc FVIII Muteins for Treatment of Von Willebrand Disease
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
EP3437661A1 (en) * 2008-10-17 2019-02-06 Baxalta GmbH Modified blood factors comprising a low degree of water soluble polymer
WO2010062768A1 (en) * 2008-11-03 2010-06-03 Bayer Healthcare Llc Method for the treatment of hemophilia
WO2010060081A1 (en) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
EP2387413A4 (en) * 2009-01-19 2015-12-23 Bayer Healthcare Llc PROTEIN CONJUGATE WITH AN ENDOPEPTIDASE-SPLICABLE BIOPROTEKTIVES PART
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
NZ593833A (en) 2009-02-03 2013-10-25 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
JP2012518029A (ja) * 2009-02-19 2012-08-09 ノヴォ・ノルディスク・アー／エス 第ｖｉｉｉ因子の修飾
HUE030373T2 (en) * 2009-03-20 2017-05-29 Hanmi Science Co Ltd A method for producing a site-specific conjugate of a physiologically active polypeptide
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
CN106110311A (zh) 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
MX2012001207A (es) 2009-07-27 2012-05-08 Baxter Int Conjugados proteicos de coagulacion sanguínea.
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3326643B1 (en) 2009-12-06 2021-04-07 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
US9254336B2 (en) * 2010-02-21 2016-02-09 Bayer Healthcare Llc Method for activation and conjugation of biomolecules
AU2011239434B2 (en) 2010-04-15 2015-04-30 Kodiak Sciences Inc. High molecular weight zwitterion-containing polymers
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EP3508573A1 (en) * 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
SG10201509149VA (en) * 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
KR20130125789A (ko) * 2010-12-16 2013-11-19 노보 노르디스크 에이/에스 수성 인자ⅷ 용액
MX345608B (es) 2010-12-22 2017-02-07 Baxalta Inc Materiales y metodos para conjugar un derivado de acido graso soluble en agua a una proteina.
JP2014520094A (ja) * 2011-05-27 2014-08-21 バクスター・インターナショナル・インコーポレイテッド 増加した半減期を有する治療用タンパク質およびそれを調製する方法
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
KR20140054009A (ko) 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
PL2729161T3 (pl) 2011-07-08 2019-08-30 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
HRP20192314T1 (hr) 2012-02-15 2020-03-20 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci pripreme i njihove uporabe
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
WO2013185113A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
HK1214539A1 (zh) 2012-10-30 2016-07-29 Bioverativ Therapeutics Inc. 應用viii因子多肽的方法
JP6387392B2 (ja) 2013-03-15 2018-09-05 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子ポリペプチド製剤
SG10201803999UA (en) * 2013-03-15 2018-06-28 Bayer Healthcare Llc Recombinant factor viii formulations
HUE047933T2 (hu) 2013-03-15 2020-05-28 Bioverativ Therapeutics Inc Faktor VIII polipeptid készítmények
RS59124B1 (sr) 2013-04-18 2019-09-30 Novo Nordisk As Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
WO2015059121A1 (en) * 2013-10-22 2015-04-30 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
CN106414491B (zh) * 2014-01-20 2021-06-18 奥克塔法马股份有限公司 一种制备FVIII:C/FVIII:Ag比例提高的因子VIII的方法
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
CA2944909A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
RU2016144057A (ru) 2014-04-10 2018-05-15 Байер Хелскеа Ллк Смешанный состав порошка среды и способ получения жидкой среды для культуры клеток
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
DK3164150T3 (da) 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
BR112017023785A2 (pt) 2015-05-22 2018-07-17 Csl Behring Recombinant Facility Ag polipeptídeos do fator de von willebrand truncados para tratar hemofilia
CN107810194B (zh) 2015-05-22 2021-10-08 康诺贝林伦瑙有限公司 用于制备经修饰的血管性血友病因子的方法
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
WO2017117631A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated truncated von willebrand factor
SG11201805494WA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
JP7235511B2 (ja) * 2016-06-24 2023-03-08 モガム・インスティテュート・フォー・バイオメディカル・リサーチ 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート
CA3043397A1 (en) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
CN109922824A (zh) 2016-11-11 2019-06-21 康诺贝林伦瑙有限公司 用于治疗血友病的截短的冯维勒布兰德因子多肽
WO2018093766A1 (en) 2016-11-16 2018-05-24 Bayer Healthcare Llc Red blood cell targeted factor viii and method of using the same
BR112019011115A2 (pt) 2016-12-02 2019-10-01 Bioverativ Therapeutics Inc métodos para tratar artropatia hemofílica usando fatores de coagulação quiméricos
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
WO2018144623A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
DK3793588T3 (da) 2018-05-18 2025-06-16 Bioverativ Therapeutics Inc Fremgangsmåder til behandling af hæmofili a
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
JP2023505208A (ja) * 2019-12-06 2023-02-08 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 第ｖｉｉｉ因子の機能を調節するための組成物および方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
EP0294910B1 (en) 1987-06-12 1996-09-11 Immuno Ag Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
HU220194B (hu) 1992-10-02 2001-11-28 Genetics Institute Inc. Koagulációs faktor VIII-at tartalmazó készítmény és eljárás előállítására
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
AU685187B2 (en) 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
EP0788375A2 (en) 1994-11-09 1997-08-13 Robin Ewart Offord Functionalized polymers for site-specific attachment
EP0776530A4 (en) * 1995-06-21 1998-06-10 Motorola Inc METHOD AND ANTENNA PRODUCING AN OMNIDIRECTIONAL RADIATION DIAGRAM
WO1997003195A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
NZ333993A (en) * 1996-08-02 2000-01-28 Ortho Mcneil Pharm Inc Compositions of EPO having a single covalently bound N-terminal water-soluble polymer
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
WO1999003887A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2306629A1 (en) * 1997-10-17 1999-04-29 Harvest Technologies Corporation Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
DE69922189T2 (de) 1998-04-27 2005-11-10 Opperbas Holding B.V. Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
DE59914490D1 (de) 1998-11-10 2007-10-18 Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
ATE526401T1 (de) 1999-01-14 2011-10-15 Bolder Biotechnology Inc Verfahren zur herstellung von proteinen mit freien cysteinresten
WO2000071714A2 (en) 1999-05-24 2000-11-30 The American National Red Cross Methods of reducing factor viii clearance and compositions therefor
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
CA2422902A1 (en) 2000-09-19 2002-03-28 Emory University Modified factor viii
AU2002248329B2 (en) 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
JP2004529640A (ja) * 2001-03-22 2004-09-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ凝固因子誘導体
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
AU2002312660A1 (en) 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
ES2331909T3 (es) 2001-06-14 2010-01-20 The Scripps Research Institute Factor viii estabilizado con enlaces disulfuro modificados geneticamente.
DE60230456D1 (de) 2001-10-05 2009-01-29 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
CA2482926A1 (en) 2002-04-18 2003-10-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified factor viii
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US7329721B2 (en) 2002-12-31 2008-02-12 Nektar Therapeutics Al, Corporation Maleamic acid polymer derivatives and their bioconjugates
ATE444984T1 (de) 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
AU2004204136B2 (en) 2003-01-06 2008-10-09 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
SI1596887T1 (sl) 2003-02-26 2022-05-31 Nektar Therapeutics Konjugati polimer-del faktorja VIII
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
EP2336162A1 (en) * 2003-05-12 2011-06-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
EP1682106A4 (en) 2003-10-30 2008-06-11 Univ Emory MODIFIED FVIII WITH REDUCED IMMUNOGENICITY BY MUTAGENESIS OF A2 AND C2 EPITOPES
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US7855274B2 (en) 2003-12-03 2010-12-21 University Of Rochester Recombinant factor VIII having increased specific activity
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
SI2363414T1 (sl) 2004-11-12 2022-09-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
EP1871801A2 (en) 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Blood coagulation fviii analogues
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII

Also Published As

Publication number Publication date
ES2633916T3 (es) 2017-09-26
ES2930159T3 (es) 2022-12-07
PL1824988T3 (pl) 2018-01-31
NL300989I1 (nl) 2019-05-22
CN103214569B (zh) 2016-12-28
SI3130601T1 (sl) 2020-11-30
NO345800B1 (no) 2021-08-09
KR20180110192A (ko) 2018-10-08
JP6487895B2 (ja) 2019-03-20
KR101468345B1 (ko) 2014-12-03
CN103102406B (zh) 2015-05-27
US7632921B2 (en) 2009-12-15
US20160051633A1 (en) 2016-02-25
CN103214569A (zh) 2013-07-24
MX350293B (es) 2017-09-04
JP6109523B2 (ja) 2017-04-05
PL2363414T3 (pl) 2022-09-05
LT1824988T (lt) 2017-10-25
PL2371856T3 (pl) 2022-08-22
EP3243834A1 (en) 2017-11-15
HUE050542T2 (hu) 2020-12-28
EP2363414A3 (en) 2012-03-21
IL182903A0 (en) 2007-08-19
KR101243564B1 (ko) 2013-03-27
CA2586379A1 (en) 2006-05-18
CN101124331A (zh) 2008-02-13
DK1824988T3 (en) 2017-08-07
MX392760B (es) 2025-03-24
CN107082806A (zh) 2017-08-22
EP3243833A1 (en) 2017-11-15
WO2006053299A2 (en) 2006-05-18
CY2019024I1 (el) 2019-11-27
AU2005304622A1 (en) 2006-05-18
PT1824988T (pt) 2017-07-21
FR19C1031I2 (fr) 2020-06-05
HRP20180481B1 (hr) 2022-02-18
IL232540A0 (en) 2014-06-30
LT3130601T (lt) 2020-09-10
BR122016022033B8 (pt) 2021-05-25
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
HN2007015683A (es) 2011-07-11
ES2930143T3 (es) 2022-12-07
IL232540A (en) 2017-08-31
KR20140019489A (ko) 2014-02-14
RU2007121517A (ru) 2008-12-20
CN105753968A (zh) 2016-07-13
CY2019024I2 (el) 2019-11-27
EP2371856A2 (en) 2011-10-05
BR122016022033B1 (pt) 2021-03-02
EP2363414A2 (en) 2011-09-07
JP2013067621A (ja) 2013-04-18
EP3323829B1 (en) 2020-07-15
RU2423380C2 (ru) 2011-07-10
BRPI0517795A (pt) 2008-10-21
BRPI0517795B8 (pt) 2021-05-25
ES2821832T3 (es) 2021-04-27
SI1824988T1 (sl) 2017-11-30
HRP20180481A2 (hr) 2018-06-29
EP2371856B1 (en) 2022-05-18
LTPA2019509I1 (lt) 2019-08-26
JP2008524117A (ja) 2008-07-10
EP2363414B1 (en) 2022-05-18
KR20120136413A (ko) 2012-12-18
NZ555032A (en) 2010-02-26
EP2772500B1 (en) 2019-12-25
EP3323829A1 (en) 2018-05-23
KR101483917B1 (ko) 2015-01-16
EP3130601B1 (en) 2020-07-15
KR20130036780A (ko) 2013-04-12
EP3243833B1 (en) 2020-06-17
PH12014500352B1 (en) 2019-09-25
HK1117875A1 (en) 2009-01-23
LTC1824988I2 (lt) 2021-02-25
EP3130601A1 (en) 2017-02-15
PT3130601T (pt) 2020-10-01
BE2019C523I2 (instruction) 2025-02-10
US9096656B2 (en) 2015-08-04
EP1824988B1 (en) 2017-04-19
NO344606B1 (no) 2020-02-10
EP2772500A1 (en) 2014-09-03
NL300989I2 (nl) 2019-11-28
EP1824988A4 (en) 2008-12-31
LT2363414T (lt) 2022-10-25
US20100081615A1 (en) 2010-04-01
FR19C1031I1 (instruction) 2019-06-28
CN105148287B (zh) 2019-07-09
CN103102406A (zh) 2013-05-15
CY1123384T1 (el) 2021-12-31
DK2363414T3 (da) 2022-08-08
JP2017105773A (ja) 2017-06-15
PH12014500352A1 (en) 2015-07-20
MA29663B1 (fr) 2008-08-01
BRPI0517795B1 (pt) 2020-03-31
KR20160105928A (ko) 2016-09-07
KR101654011B1 (ko) 2016-09-05
NO20200044A1 (no) 2007-06-27
HUE033776T2 (en) 2018-01-29
EP2371856A3 (en) 2012-03-14
KR20070110260A (ko) 2007-11-16
BRPI0517795A8 (pt) 2018-12-26
KR20140091618A (ko) 2014-07-21
EP3153181A1 (en) 2017-04-12
EP1824988A2 (en) 2007-08-29
WO2006053299A3 (en) 2006-08-24
MX2007005466A (es) 2007-10-19
LUC00118I1 (instruction) 2019-05-13
UA95225C2 (ru) 2011-07-25
AU2005304622B2 (en) 2012-03-29
LT2371856T (lt) 2022-08-25
JP2017101028A (ja) 2017-06-08
CN101124331B (zh) 2013-04-24
CY1119292T1 (el) 2018-02-14
JP2015134780A (ja) 2015-07-27
KR101904630B1 (ko) 2018-10-04
IL182903A (en) 2014-09-30
HUE059193T2 (hu) 2022-10-28
ZA200703696B (en) 2008-08-27
JP6559642B2 (ja) 2019-08-14
HRP20070268B1 (hr) 2018-04-20
HUE060016T2 (hu) 2023-01-28
HK1218718A1 (zh) 2017-03-10
NO20072997L (no) 2007-06-27
SI2371856T1 (sl) 2022-09-30
DK2371856T3 (en) 2022-08-08
US20060115876A1 (en) 2006-06-01
PH12019501613A1 (en) 2020-09-14
CN105148287A (zh) 2015-12-16
US9364520B2 (en) 2016-06-14
LUC00118I2 (instruction) 2019-12-27
CA2586379C (en) 2012-04-03
JP6018238B2 (ja) 2016-11-02
HRP20070268A2 (hr) 2007-09-30
HUS1900026I1 (hu) 2022-04-28
PT2363414T (pt) 2022-08-04
US20130274445A1 (en) 2013-10-17
HK1182121A1 (en) 2013-11-22
IL234433B (en) 2019-11-28

Similar Documents

Publication Publication Date Title
IL234433B (en) Site-directed modification of factor viii
GB0426503D0 (en) Improved osteotome
IL183634A0 (en) Polymer-von willebrand factor-conjugates
ZA200606315B (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
EP1802588A4 (en) SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
EP1773871A4 (en) COMPOUNDS ASSOCIATED WITH TISSUE DIFFERENTIATION FACTOR AND THEIR ANALOGUES
EP1785131A4 (en) EXTERNAL PREPARATION OF TYPE S / O
AU300055S (en) Scrubber
PL1720633T3 (pl) Płuczka wieżowa gazu
GB0428026D0 (en) Infant aid
GB0418912D0 (en) Improved building components
GB2416051B (en) Selection of component
ZA200508325B (en) Manufacture of kerbstones
GB0421155D0 (en) Piece of mind plan
GB0415217D0 (en) Compounds and uses thereof
GB0412872D0 (en) Novel structures
PL369353A1 (pl) Zestaw elementów budowlanych
AU157294S (en) External cornice corner member
TWM275831U (en) Improved structure of cinerary urn
SI1835938T1 (sl) Konjugati polimera in von Willebrandovega faktorja
GB0414968D0 (en) Novel preparation
GB0402464D0 (en) Child walker